表紙
市場調査レポート

女性の健康:米国の生殖管理製品市場

Women's Health: U.S. Markets for Reproductive Management Products

発行 Medtech Insight 商品コード 289910
出版日 ページ情報 英文 132 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
女性の健康:米国の生殖管理製品市場 Women's Health: U.S. Markets for Reproductive Management Products
出版日: 2013年09月30日 ページ情報: 英文 132 Pages
概要

米国の生殖管理製品市場は、2013年の市場規模が推計37億米ドル以上で、巨大で強固な市場となっています。避妊薬、避妊具/インプラント、排卵誘発剤などが対象で、CAGRで7%以上の成長が予測されています。

当レポートでは、米国の生殖管理製品市場について調査分析し、製品、競合企業、新興の技術と機会について検証して、概略以下の構成でお届けいたします。

第1章 避妊薬・避妊具

  • 避妊薬
  • 避妊具
  • 非外科的避妊法

第2章 排卵誘発剤・デバイス

  • 主な不妊治療薬
  • 胚移植カテーテル
  • 自然妊娠の補助

第3章 企業プロファイル

  • Actavis, Inc.
  • Bayer AG
  • Ferring Pharmaceuticals A/S
  • Johnson & Johnson
  • Merck & Company, Inc.
  • Merck KGaA
  • Teva Pharmaceuticals/Teva Pharmaceutical Industries Ltd.

付録

目次
Product Code: A471

The U.S. market for reproductive management products is large and robust, estimated at more than $3.7 billion in 2013. This market, which includes a broad range of contraceptive drugs, contraceptive devices/implants, and fertility drugs, is expected to expand at a healthy compound annual growth rate of more than 7%, increasing by more than $1.5 billion over a span of 5 years.

Despite a sluggish economy, intense competition, pricing pressures, litigation, and the significant impact of generic contraceptives, growth in this market is expected to accelerate at a better than average pace throughout the forecast period, as the contraceptives segment, in particular, benefits from highly positive insurance reimbursement (as a result of the 2010 Affordable Care Act) and increasing consumer affordability. The contraceptives market is also expected to flourish due to the introduction of several safer, more tolerable, lower-dosage, yet highly effective contraceptive drugs, and strong advertising/marketing efforts by major pharmaceutical firms. Additionally, the market is benefiting from increased consumer preference and usage of novel contraceptive devices and implants, which provide a convenient, long-term alternative for preventing pregnancy, especially in women who cannot tolerate, or fail to adhere to required dosing schedules of oral drug therapies.

The U.S. market for reproductive management products will also benefit from continued strong demand for easier-to-use, highly effective fertility drugs, as well as the introduction of new technologies, which are expected to enhance assisted reproductive technology and further improve pregnancy rates and decrease potential side effects.

Overall, the U.S. market for reproductive management products will continue to benefit from the stability and growth of the aging female population in the U.S., which continues to postpone or refrain from childbearing and demand access to highly effective contraceptives and fertility drugs.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, emerging technology and opportunities. Covered products include oral, transdermal, injectable and emergency contraceptives; contraceptive devices, including intrauterine devices (IUDs), vaginal rings, and subdermal contraceptive implants; and leading fertility drug therapies and devices, among other products.

Table of Contents

EXECUTIVE SUMMARY

  • i. Contraceptive Drugs and Devices
  • ii. Fertility Treatment
  • iii. Combined Market Forecast
  • iv. Methodology
  • Exhibit ES-1: Reproductive Management Products Market, Combined Market Forecast, 2012-2017
  • Exhibit ES-2: Reproductive Management Products, Market Forecast, by Product Segment, 2012-2017
  • Exhibit ES-3: 2012, Reproductive Management Products Market, Share of Sales, by Product Segment
  • Exhibit ES-4: 2017, Reproductive Management Products Market, Share of Sales, by Product Segment

1. CONTRACEPTIVE DRUGS AND DEVICES

  • 1.1. Contraceptive Drugs
    • 1.1.1. Actavis
    • 1.1.2. Bayer
    • 1.1.3. Janssen Pharmaceuticals/Johnson & Johnson
    • 1.1.4. Merck & Company
    • 1.1.5. Pfizer
    • 1.1.6. Teva Pharmaceuticals/Teva Pharmaceutical Industries
    • 1.1.7. Market Forecast
    • 1.1.8. Competitive Analysis
  • 1.2. Contraceptive Devices
    • 1.2.1. Actavis
    • 1.2.2. Bayer
    • 1.2.3. The Female Health Company
    • 1.2.4. FemCap
    • 1.2.5. Mayer Laboratories
    • 1.2.6. Merck & Company
    • 1.2.7. Teva Pharmaceuticals/Teva Pharmaceutical Industries
    • 1.2.8. Market Forecast
    • 1.2.9. Competitive Analysis
  • 1.3. Nonsurgical Sterilization
    • 1.3.1. Bayer
    • 1.3.2. Hologic
  • Exhibit 1-1: 2013, Selected Contraceptive Drugs
  • Exhibit 1-2: 2013, Selected Contraceptive Drugs Under Development
  • Exhibit 1-3: The Average Reduction in Menstrual Bleeding Using Natazia Over a 90-day Assessment Phase in 2 Studies
  • Exhibit 1-4: Contraceptive Drugs, Market Forecast, 2012-2017
  • Exhibit 1-5: 2012, Contraceptive Drugs Market, Share by Supplier
  • Exhibit 1-6: 2013, Selected Leading Contraceptive Devices
  • Exhibit 1-7: 2013, Selected Contraceptive Devices Under Development
  • Exhibit 1-8: The Mirena Intrauterine Device
  • Exhibit 1-9: The FemCap Cervical Cap
  • Exhibit 1-10: The NuvaRing Vaginal Contraceptive Ring
  • Exhibit 1-11: Efficacy of the NuvaRing Compared to Other Contraceptive Methods
  • Exhibit 1-12: The Implanon Subdermal Contraceptive Implant
  • Exhibit 1-13: Efficacy of Implanon Compared to Other Contraceptive Methods
  • Exhibit 1-14: The ParaGard Intrauterine Device
  • Exhibit 1-15: Contraceptive Devices, Market Forecast, 2012-2017
  • Exhibit 1-16: 2012, Contraceptive Devices Market, Share by Supplier
  • Exhibit 1-17: The Essure Three-Step Sterilization Procedure

2. FERTILITY DRUGS AND DEVICES

  • 2.1. Selected Fertility Drug Treatments
    • 2.1.1. Actavis
    • 2.1.2. EMD Serono/Merck KGaA
    • 2.1.3. Ferring Pharmaceuticals
    • 2.1.4. Merck & Company
    • 2.1.5. OvaScience
    • 2.1.6. Teva Pharmaceuticals/Teva Pharmaceutical Industries
    • 2.1.7. Market Forecast
    • 2.1.8. Competitive Analysis
  • 2.2. Embryo Transfer Catheters
    • 2.2.1. CooperSurgical/The Cooper Companies
    • 2.2.2. Irvine Scientific/JX Group
  • 2.3. Assisted Natural Conception
    • 3.3.1. Cambridge Temperature Concepts
  • Exhibit 2-1: 2013, Selected Fertility Drug Therapies
  • Exhibit 2-2: 2013, Selected Immunoassays and Fertility Treatments Under Development
  • Exhibit 2-3: Efficacy of Crinone in Maintaining Full-Term Pregnancies Following In Vitro Fertilization Embryo Transfer
  • Exhibit 2-4: Efficacy of Crinone in Maintaining Full-Term Pregnancies versus No Supplemental Progesterone for Luteal Phase Support
  • Exhibit 2-5: The Gonal-f RFF Pen
  • Exhibit 2-6: Fertility Drugs, Market Forecast, 2012-2017
  • Exhibit 2-7: 2012, Fertility Drugs Market, Share by Supplier
  • Exhibit 2-8: The R.G. Edwards Embryo Transfer Catheters
  • Exhibit 2-9: The Classic Ultrasoft Embryo Transfer Catheters and Stylets
  • Exhibit 2-10: The DuoFertility Assisted Natural Conception System

3. COMPANY PROFILES

  • 3.1. Actavis, Inc.
  • 3.2. Bayer AG
  • 3.3. Ferring Pharmaceuticals A/S
  • 3.4. Johnson & Johnson
  • 3.5. Merck & Company, Inc.
  • 3.6. Merck KGaA
  • 3.7. Teva Pharmaceuticals/Teva Pharmaceutical Industries LTD

APPENDIX: COMPANY LISTING

Back to Top